RxDoctor Payments Data

Tahir Abbasi, MD

Cardiovascular Disease · Hazel Crest, ILNPI 1255495701

Payments from drug & device makers

$129,312in general payments, 2019–2025

Across 255 payments — averaging $507.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$63K
  • Novo Nordisk$31K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$20K
  • Alnylam Pharmaceuticals Inc.$12K
  • AstraZeneca$649
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$583
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$2,96598%
  • Education$462%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$129,312 in reported general payments places this provider in the 90th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$85,844
Medicare patients
328
Services billed
834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan257$198,910
EliquisApixaban127$108,770
XareltoRivaroxaban74$46,193
FarxigaDapagliflozin Propanediol62$45,280
JardianceEmpagliflozin46$45,040
MounjaroTirzepatide29$33,812
JanuviaSitagliptin Phosphate28$27,290
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$18,298
VerquvoVericiguat23$14,699
Repatha SureclickEvolocumab25$14,459
RybelsusSemaglutide11$10,747
Tresiba Flextouch U-100Insulin Degludec14$10,005
Combivent RespimatIpratropium/Albuterol Sulfate14$8,485
MyrbetriqMirabegron18$8,339
Breo ElliptaFluticasone/Vilanterol20$8,047

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$233$198,910257 claims
AstraZenecaFarxiga, Brilinta, Symbicort$649$59,784101 claims
Boehringer IngelheimJardiance, Combivent Respimat$22$53,52560 claims
MerckJanuvia, Verquvo, Dulera$397$46,84965 claims
Johnson & JohnsonXarelto$16$46,19374 claims
Lilly USA, LLCMounjaro$474$33,81229 claims
Novo NordiskRybelsus$31,164$10,74711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Hazel Crest

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →